Risk minimisation materials
The ELIQUIS® (apixaban) Prescriber Guide and Patient Alert Card are risk minimisation materials developed for all indications, aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban and providing guidance on how to manage that risk.
More information on each of these documents can be found
at www.medicines.org.uk/emc/product/2878/rmms (5 mg)
or www.medicines.org.uk/emc/product/4756/rmms (2.5 mg).
Please click here to access the ELIQUIS Patient Information Leaflet.
BD = Twice Daily
DVT = Deep Vein Thrombosis
NVAF = Non-Valvular Atrial Fibrillation
PE = Pulmonary Embolism
SmPC = Summary of Product Characteristics
* ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor indicated for:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA);
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
- Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1
†Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.
Reference
- ELIQUIS® (apixaban) Summary of Product Characteristics.